Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2019

29.04.2019 | Health Services Research and Global Oncology

Changing Trends in Industry Funding for Surgical Oncologists

verfasst von: Juan A. Santamaria-Barria, MD, Stacey Stern, MS, Adam Khader, MD, Mary Garland-Kledzik, MD, Anthony J. Scholer, MD, Trevan Fischer, MD, FACS, Anton Bilchik, MD, PhD, MBA, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

With reductions in public funding, alternate research funding is essential to surgical oncologists (SOs). We aimed to examine current trends in industry funding of SOs.

Methods

Society of Surgical Oncology surgeons were identified and matched with board certification and years in practice. Departmental and hospital data were evaluated, and industry payments from 2013 to 2017 were matched with the Open Payment Data.

Results

Of the 1670 SOs identified, 922 (55%) had academic positions: 588 (64%) males and 334 (36%) females. Between 2013 and 2017, research payments totaling $46,596,706 were made to 162 SOs (17.5%): $40,774,716 (87%) for research related to drugs and clinical trials, compared with $5,194,199 (11%) for surgical devices (p = 0.018). Funding correlated with academic leadership and years in practice (p = 0.0001 and p = 0.0037). Massachusetts ($9,060,976), Texas ($7,656,228), and New York ($4,210,864) received the most funding, whereas Utah ($1,533,166/SO), Massachusetts ($1,294,425/SO), and Oregon ($1,241,702/SO) received the highest average payments per SO. The majority of funding was from Novartis ($16,045,608), Amgen ($6,810,832), and Merck ($3,758,299), for an oncolytic vaccine (talimogene laherparepvec, $5,939,007), a BRAF inhibitor (dabrafenib, $5,727,309), and a KIT inhibitor (imatinib, $4,323,586). Male SOs received funding more frequently than females (120/588 [20%] vs. 42/334 [12.6%]; p = 0.0027). Males also received more general payments (travel/lodging, food/beverage, consulting/speaker fees): $48,830 vs. $11,867 per male and female, respectively (p = 0.0001).

Conclusions

The majority of industry research payments to SOs are related to novel pharmaceuticals, which highlights the expanding influence SOs play in systemic therapies. Industry payments are influenced by location, gender, and academic leadership.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Keswani SG, Moles CM, Morowitz M, et al. The future of basic science in academic surgery: identifying barriers to success for surgeon-scientists. Ann. Surg. 2017;265(6):1053–1059.CrossRefPubMedPubMedCentral Keswani SG, Moles CM, Morowitz M, et al. The future of basic science in academic surgery: identifying barriers to success for surgeon-scientists. Ann. Surg. 2017;265(6):1053–1059.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kibbe MR, Velazquez OC. The extinction of the surgeon scientist. Ann. Surg. 2017;265(6):1060–1061.CrossRefPubMed Kibbe MR, Velazquez OC. The extinction of the surgeon scientist. Ann. Surg. 2017;265(6):1060–1061.CrossRefPubMed
5.
Zurück zum Zitat Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc. Natl. Acad. Sci. USA. 2018;115(10):2329–2334.CrossRefPubMedPubMedCentral Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc. Natl. Acad. Sci. USA. 2018;115(10):2329–2334.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. JAMA. 2015;314(23):2566–2567.CrossRefPubMedPubMedCentral Ehrhardt S, Appel LJ, Meinert CL. Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. JAMA. 2015;314(23):2566–2567.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chopra SS. MSJAMA: Industry funding of clinical trials: benefit or bias? JAMA. 2003;290(1):113–114.CrossRefPubMed Chopra SS. MSJAMA: Industry funding of clinical trials: benefit or bias? JAMA. 2003;290(1):113–114.CrossRefPubMed
12.
Zurück zum Zitat Narahari AK, Mehaffey JH, Hawkins RB, et al. Surgeon scientists are disproportionately affected by declining NIH funding rates. J. Am. Coll. Surg. 2018;226(4):474–481.CrossRefPubMedPubMedCentral Narahari AK, Mehaffey JH, Hawkins RB, et al. Surgeon scientists are disproportionately affected by declining NIH funding rates. J. Am. Coll. Surg. 2018;226(4):474–481.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Wayant C, Turner E, Meyer C, Sinnett P, Vassar M. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncol. 2018;4(10):1426–1428.CrossRefPubMedPubMedCentral Wayant C, Turner E, Meyer C, Sinnett P, Vassar M. Financial conflicts of interest among oncologist authors of reports of clinical drug trials. JAMA Oncol. 2018;4(10):1426–1428.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Olavarria OA, Holihan JL, Cherla D, et al. Comparison of conflicts of interest among published hernia researchers self-reported with the centers for medicare and medicaid services open payments database. J. Am. Coll. Surg. 2017;224(5):800–804.CrossRefPubMed Olavarria OA, Holihan JL, Cherla D, et al. Comparison of conflicts of interest among published hernia researchers self-reported with the centers for medicare and medicaid services open payments database. J. Am. Coll. Surg. 2017;224(5):800–804.CrossRefPubMed
15.
Zurück zum Zitat Nguyen V, Marmor RA, Ramamoorthy SL, Blair SL, Clary BM, Sicklick JK. Academic surgical oncologists’ productivity correlates with gender, grant funding, and institutional NCI comprehensive cancer center affiliation. Ann. Surg. Oncol. 2018;25(7):1852–1859.CrossRefPubMedPubMedCentral Nguyen V, Marmor RA, Ramamoorthy SL, Blair SL, Clary BM, Sicklick JK. Academic surgical oncologists’ productivity correlates with gender, grant funding, and institutional NCI comprehensive cancer center affiliation. Ann. Surg. Oncol. 2018;25(7):1852–1859.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Patel SV, Yu D, Elsolh B, Goldacre BM, Nash GM. Assessment of conflicts of interest in robotic surgical studies: validating author’s declarations with the open payments database. Ann. Surg. 2018;268(1):86–92.CrossRefPubMedPubMedCentral Patel SV, Yu D, Elsolh B, Goldacre BM, Nash GM. Assessment of conflicts of interest in robotic surgical studies: validating author’s declarations with the open payments database. Ann. Surg. 2018;268(1):86–92.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Ziai K, Pigazzi A, Smith BR, et al. Association of compensation from the surgical and medical device industry to physicians and self-declared conflict of interest. JAMA Surg. 2018;153(11):997–1002.CrossRefPubMedPubMedCentral Ziai K, Pigazzi A, Smith BR, et al. Association of compensation from the surgical and medical device industry to physicians and self-declared conflict of interest. JAMA Surg. 2018;153(11):997–1002.CrossRefPubMedPubMedCentral
Metadaten
Titel
Changing Trends in Industry Funding for Surgical Oncologists
verfasst von
Juan A. Santamaria-Barria, MD
Stacey Stern, MS
Adam Khader, MD
Mary Garland-Kledzik, MD
Anthony J. Scholer, MD
Trevan Fischer, MD, FACS
Anton Bilchik, MD, PhD, MBA, FACS
Publikationsdatum
29.04.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07380-1

Weitere Artikel der Ausgabe 8/2019

Annals of Surgical Oncology 8/2019 Zur Ausgabe

Health Services Research and Global Oncology

Resolve the Conflict Rather than Dissolve the Relationship

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.